The use of DHEA is commonly applied in therapeutic domains where additional symptomatic support is needed, relevant in contexts marked by increased discomfort or tension. The medication is commonly used to help with symptoms related to physical discomfort, specifically for moderate to severe dyspareunia, which is painful sexual intercourse and a key symptom of vulvar and vaginal atrophy due to menopause.

The medication plays a role in managing symptoms related to genitourinary comfort, is relevant for easing symptoms in adrenal insufficiency, and may assist with managing persistent low mood or fatigue in specific patient groups. This assists with maintaining functional stability and supports general well-being during symptomatic phases.

“DHEA supports patients during difficult episodes by easing distress and contributing to improved day-to-day comfort.”

In specialized clinical settings, DHEA is also applied as an adjuvant support for women diagnosed with low ovarian reserve undergoing assisted reproduction treatments.

Quick Fact: Relief for Dyspareunia
DHEA is commonly used to address moderate to severe pain during sexual activity resulting from postmenopausal vulvar and vaginal atrophy.

Eligibility Map: Who can and cannot use Dehydroepiandrosterone (Prasterone)

Official regulatory information strictly limits the use of prasterone to specific populations based on its hormonal activity. The medicine is primarily intended for postmenopausal women seeking treatment for moderate to severe pain during sexual intercourse due to vulvar and vaginal atrophy (VVA).

---

Absolute Contraindications

Prasterone must not be used by women with the following conditions, as stated in regulatory labeling:

• Known, past, or suspected breast cancer or any other known or suspected oestrogen-dependent malignant tumours.
• Undiagnosed abnormal genital bleeding.
• Known or suspected pregnancy or while breast-feeding (lactating).
• Untreated endometrial hyperplasia.

---

Restricted and Non-Recommended Use

Use is not recommended for pediatric patients (children and adolescents) as safety and efficacy have not been established. Use also requires close supervision in patients with specific comorbidities, including liver disorders, hypertension, diabetes mellitus, and a history of risk factors for venous thromboembolism (VTE). Patients with hepatic or renal impairment should use with caution due to limited data.

Interactions with other medicines and products

The official regulatory profile for Prasterone (Дегидроэпиандростерон) vaginal insert is characterized by a minimal risk of systemic drug interactions, largely due to its localized administration and limited systemic absorption. Because dedicated drug-drug interaction (DDI) studies for this formulation were not performed, the regulatory classification is one of no known systemic drug interactions.

Metabolic and Exposure Profile

Regulatory data review of in vitro studies indicated that the active substance does not inhibit the activity of major cytochrome P450 (CYP) enzymes, including CYP1A2, CYP2C9, and CYP3A4. This finding suggests a low potential for the medicine to alter the plasma levels of other co-administered systemic drugs through metabolic interference. The official label makes no specific documented statements regarding interactions with food, alcohol, or common herbal products.

Co-administration Restrictions

Specific official restrictions apply to co-administration with other hormonal therapies and local products, as these combinations have not been formally investigated:

• Systemic Hormone Therapies: Use is not recommended with systemic hormone replacement therapy, including estrogen-only, estrogen-progestogen combinations, or androgen treatments.
• Vaginal Products: Co-administration with other vaginal products, including vaginal estrogens, is not recommended due to the lack of clinical data on simultaneous use.

How Дегидроэпиандростерон works: Mechanism of Action

The biological activity of Дегидроэпиандростерон ( DHEA) is centered on three distinct mechanistic domains. Primarily, DHEA functions as a ubiquitous extbfprohormone, undergoing extbfintracrine conversion in peripheral tissues into more active sex steroids, including testosterone and estradiol. These metabolites then bind to and activate extbfnuclear steroid hormone receptors ( AR and ER), initiating extbfgenomic signaling that alters gene expression, which results in anabolic signaling influencing muscle protein synthesis and osteoblast activity.

Simultaneously, DHEA acts as a extbfneurosteroid in the Central Nervous System ( CNS). This involves a extbfrapid, non-genomic modulation of key neuronal membrane targets, such as the extbfGABA extbfA receptor and the extbfNMDA receptor. This interaction extbfmodulates neuronal excitability and influences central signaling pathways.

Thirdly, DHEA engages in extbfenzyme inhibition, notably acting as a non-competitive extbfinhibitor of Glucose-6-Phosphate Dehydrogenase ( G6PD). This alters the cellular extbfredox state and NADPH production within the extbfpentose phosphate pathway, modifying molecular steps that influence systemic physiological processes, including immune cell function and cellular metabolism.

The administration of Дегидроэпиандростерон (Prasterone) is structured by instructions that vary depending on the dosage form. The most widely prescribed product is the 6.5 mg vaginal insert. This form is administered intravaginally once daily, with the specific instruction to be used at bedtime.

The standard dose for this intravaginal product is 6.5 mg as a single insert. The administration involves using the provided disposable applicator or a clean finger, ensuring the insert is placed as far into the vagina as comfortable. Due to the local nature of the vaginal therapy, no dose adjustment is required for patients with hepatic or renal impairment.

For certain oral formulations of Prasterone (200 mg softgel), the dosing is 200 mg once daily, which can be taken with or without food.

Therapy is designed for continuous, long-term use, though the need for continued treatment must be reassessed by a healthcare provider, typically every 3 to 6 months. If a dose of the vaginal insert is forgotten, a specific protocol is followed: if the next scheduled dose is due in less than eight hours, the missed dose must be skipped, and doses should never be doubled to compensate.

Research evidence / Overview of Studies for Дегидроэпиандростерон (DHEA)

---

Evidence for Use in Symptoms of Vulvar and Vaginal Atrophy (Dyspareunia)

Research for DHEA was conducted through high-quality randomized, double-blind, placebo-controlled Phase III clinical trials (RCTs) to examine symptoms of vulvar and vaginal atrophy, specifically pain at sexual activity (dyspareunia). These studies used a specific local, intravaginal formulation (Prasterone) in postmenopausal women. Researchers explored how symptoms change over time and measured both patient-reported discomfort scores and objective markers like vaginal pH and cellular changes. The clinical trials involved in the regulatory review of this formulation reported meeting predefined endpoints, as described in the trial results. However, the evidence is highly concentrated on the local formulation, and long-term effects extending beyond the initial 12-week study period are not fully established.

---

Evidence for Use as Adjuvant Support in Assisted Reproduction

The research landscape exploring DHEA was conducted in assisted reproduction for women with low ovarian reserve. Evidence consists of systematic reviews and meta-analyses of smaller RCTs and non-randomized studies. These studies explored reproductive endpoints such as live birth rates, clinical pregnancy rates, and functional biomarkers like AMH levels. Studies report that the measurements of reproductive outcomes varied widely across the trials. The research base is characterized by high heterogeneity and reliance on non-RCTs. Certainty remains low for many applications due to inconsistent findings and modest sample sizes.

---

Evidence for Use in Adrenal Insufficiency and Research Gaps

DHEA was evaluated in individuals with adrenal insufficiency who were already receiving standard hormone therapy. Studies evaluated whether DHEA was associated with changes in Health-Related Quality of Life (HRQOL) scores, depression, and sexual function. Meta-analyses reported a small, statistically defined pattern of differences in global HRQOL and depression scores in women. However, major scientific guideline bodies have stated that the available evidence is insufficient to support the routine incorporation of DHEA in the standard treatment protocol. Follow-up durations were limited across most studies, and data for special populations, such as pediatric groups or those with significant comorbidities, remain insufficient.

Common questions about Дегидроэпиандростерон (FAQ)

---

Q: What is the difference between DHEA and other hormonal supplements?

Regulatory documents classify Dehydroepiandrosterone (Prasterone) as an endogenous steroid prohormone, meaning it is a precursor to other hormones produced naturally by the body. Because of its hormonal activity, official product information indicates that the medicine is not recommended for use with systemic hormone replacement therapies, such as estrogen or estrogen-progestogen combinations.

Q: How long must I take DHEA to see an effect?

Clinical trials reviewed for regulatory approval, which focused on relieving pain during sexual activity (dyspareunia), typically assessed efficacy over a period of 12 weeks. The studies focused on symptom changes over this period.

Q: Can I take DHEA with other vitamins or supplements?

Official information states that the medicine has no known systemic drug interactions because of its localized route of administration. However, co-administration with other vaginal products is officially not recommended due to a lack of clinical data on their simultaneous use.

Q: Is it safe to take DHEA with high blood pressure?

Regulatory documents specify that the use of this medicine requires close supervision by a healthcare provider for patients with pre-existing conditions, including hypertension (high blood pressure). This is a factor that typically requires monitoring throughout the course of treatment.

Q: Can DHEA affect blood sugar levels?

Official documents recommend close professional monitoring for individuals with diabetes mellitus. This is because the medicine may influence metabolic factors like blood sugar.

Q: Is it true that DHEA can help with weight loss?

Official safety documents list weight increase as a documented common adverse reaction observed in clinical studies. The official regulatory description does not include weight loss as an intended effect.

Q: Are there differences in DHEA effects for different genders?

The medicine is officially approved for use in postmenopausal women to treat symptoms of vulvar and vaginal atrophy. Safety and efficacy have not been established in men for the approved indication, and clinical trials were focused exclusively on the female population.

Q: Does DHEA affect bone mineral density?

Studies examined by regulatory bodies report that Dehydroepiandrosterone can influence osteoblast activity, which relates to the formation of bone. Researchers have investigated its potential effect on changes in overall bone mineral density.

Q: Is there data on the long-term safety of taking DHEA?

Official safety data for the approved formulation extends only to a maximum of one year. Due to this limitation, the need for continued, long-term treatment must be formally reviewed by a healthcare provider at least annually.

Q: Does DHEA affect cholesterol levels?

Sources related to official drug information indicate the drug may lower HDL cholesterol (often called 'good' cholesterol) and raise triglyceride levels. Changes in lipid profile are typically evaluated when this type of therapy is used.

Q: Can DHEA cause body or facial hair growth?

Yes, hirsutism (excessive hair growth on the face or body) is listed in official documentation as a common, androgen-related adverse reaction. This occurs because the medicine acts as a prohormone for androgenic sex steroids.

Q: Can I take DHEA with an existing hormonal imbalance?

Official information states the medicine is contraindicated in women who have a history of, or known susceptibility to, oestrogen-dependent malignant tumours (cancers). Additionally, co-administration with systemic hormone replacement therapy is not recommended.

Q: Is a prescription needed to buy DHEA?

For the specific pharmaceutical formulation, Prasterone is generally classified as a prescription medicine ( Rx only) in countries like the United States for the approved indications. The regulatory status of DHEA products generally varies by country.

Q: Does DHEA affect mood or sleep?

Research has investigated the effects of the medicine on the central nervous system, examining changes in areas such as mood, depression scores, and sleep structure. Some studies have reported observed differences in these neurological outcomes.

Q: Why is DHEA popular among athletes?

Dehydroepiandrosterone is classified by the World Anti-Doping Agency (WADA) as an Anabolic Androgenic Steroid (AAS) precursor. It is explicitly listed as a prohibited substance in sport due to its potential to be metabolized into testosterone and related compounds.

Q: What happens if I miss a dose of DHEA?

Official administration instructions specify a protocol for missed doses. For the vaginal insert, if the next scheduled dose is due in less than eight hours, the missed dose must be skipped. Doses should never be doubled to make up for a missed application.

Q: Do I need to take breaks from DHEA?

The therapy is designed for continuous, long-term use for the approved indication. However, because official safety data is limited to one year, the necessity for continued treatment must be formally reassessed by a healthcare provider at least annually.

Q: How do I know if DHEA is right for me?

The medicine is approved for a specific condition (vulvar and vaginal atrophy) in a specific population (postmenopausal women). Eligibility is determined by these factors and whether you have any conditions that are official contraindications, such as certain types of cancer.

Q: What is the scientific evidence for DHEA for increasing energy?

Research has investigated the medicine's association with improvements in Health-Related Quality of Life (HRQOL) scores. Some non-prescription forms of DHEA have historically been marketed with claims related to temporary relief of symptoms including low energy.

Q: In what forms is DHEA available (tablets, capsules, cream)?

The pharmaceutical form of the medicine is available as an intravaginal insert (6.5 mg) for its approved use. Other formulations, such as an oral softgel capsule (200 mg), may be available in certain markets, and its status depends on local regulations.

Q: Is DHEA used as hormone replacement therapy?

While the product contains a hormone precursor, official labeling indicates that its use is not recommended with systemic hormone replacement therapies (HRT), which includes both estrogen-only and estrogen-progestogen combinations.

Q: Are there time limits for taking DHEA?

The safety data for continuous use of the drug extends only to one year. Therefore, while continuous use is allowed, a healthcare provider must formally reassess the necessity of continuing treatment at least once a year.

Q: Which DHEA studies are considered most authoritative?

The regulatory approval of the pharmaceutical product was based on high-quality studies known as randomized, double-blind, placebo-controlled Phase III clinical trials (RCTs). These types of trials are considered the most authoritative evidence for establishing efficacy.

Q: What should I do if side effects from DHEA do not go away?

Instructions for patients in the official labeling state that a healthcare provider should be contacted if a side effect is experienced or persists.

Q: Is DHEA legal to buy in my country?

The pharmaceutical formulation of Prasterone is typically classified as a prescription medicine ( Rx only) in the US and EU for its specific medical indication. The classification of DHEA products (prescription vs. supplement) varies significantly by country.

Q: Can DHEA cause insomnia?

Research has been conducted to observe effects on sleep structure, consistent with its role in modulating neuronal excitability.

Q: What is the connection between DHEA and stress?

Scientific literature indicates that Dehydroepiandrosterone (DHEA) levels can change temporarily and may be used as a biomarker of acute stress.

How to Store and Dispose of Dehydroepiandrosterone (Prasterone)

---

Official Storage Requirements

Prasterone must be stored at controlled room temperature, typically defined as 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C. It is mandatory to store the medicine in its original carton until the time of use to ensure protection from light. The product must not be frozen and should be protected from excessive heat, as this can cause the insert to melt.

Child Safety and Disposal

To prevent accidental ingestion, the medicine must always be kept out of the sight and reach of children. Unused or expired Prasterone must not be disposed of via household trash or flushed down the toilet. Disposal should be carried out in accordance with local regulatory requirements to ensure proper environmental handling.